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Objective To characterize the rates, root causes, and clinical effects of unintentional exposures to buprenorphine
sublingual formulations among young children and to determine whether exposure characteristics differ between
formulations.
Study design Unintentional exposures to buprenorphine-containing products among children 28 days to less
than 6 years old were collected from the Researched Abuse, Diversion, and Addiction-Related Surveillance System
Poison Center Program and Reckitt Benckiser Pharmaceuticals’ pharmacovigilance system from October 2009-
March 2012. After adjustment for drug availability, negative binomial regression was used to estimate average
exposure rates. Root cause assessment was conducted, and an expert clinician panel adjudicated causality and
severity of moderate to severe adverse events (AEs).
Results A total of 2380 cases were reviewed, including 4 deaths. Exposures to buprenorphine-naloxone combi-
nation film were significantly less frequent than exposures to buprenorphine tablets (rate ratio 3.5 [95%CI, 2.7-4.5])
and buprenorphine-naloxone combination tablets (rate ratio 8.8 [7.2-10.6]). The most commonly identified root
causes were medication stored in sight, accessed from a bag or purse, and not stored in the original packaging.
Among 536 panel review cases, the most common AEs reported for all formulations were lethargy, respiratory
depression, miosis, and vomiting. The highest level AE severity did not differ significantly by formulation.
Conclusions Unintentional exposure to buprenorphine can cause central nervous system depression, respira-
tory depression, and death in young children. Exposure rates to film formulations are significantly less than to tablet
formulations. Package and storage deficiencies contribute to unintentional exposures in young children. (J PediatrFrom the 1Rocky Mountain Poison and Drug Center,
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nintentional poisonings among children are an important public health
problem.1-3 One out of 180 two-year-olds visits an emergency
department for a medication poisoning each year.4 Several opioids,
including buprenorphine, have been recognized for their potential to cause death
in children with a single dose.5,6 During 2010-2011, an average of 1499 children
aged less than 6 years were evaluated in emergency departments in the US each
year for unintentional exposure to buprenorphine.7
Buprenorphine, a potent partial agonist of the mu-opioid receptor, was
introduced in the US in 2002 to treat opioid addiction in adults.8,9 Buprenor-
phine ingestion by young children can cause central nervous system depression,
respiratory depression, and death.10 Little is known about the root causes of
unintentional exposure to opioids in young children, including whether formu-
lation and child-resistant packaging affect the risk of poisoning.2,6,11,12
In the US, 3 sublingual formulations of buprenorphine are available: single-
ingredient tablets containing buprenorphine, buprenorphine-naloxone combi-
nation tablets, and buprenorphine-naloxone combination film. The opioid
antagonist naloxone, which is poorly absorbed orally, is included in the combi-
nation formulations to deter abuse by nasal insufflation (“snorting”) or
injection. The tablet formulations are typically dispensed in medication bottlesFDA Dockets Management website by searching for
“FDA-2012-P-1028” at www.regulations.gov.
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RADARS Researched Abuse, Diversion, and Addiction-Related Surveillance
REMS Risk evaluation and mitigation strategies
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THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 163, No. 5with child-resistant caps, and the film formulation, which
was released in October 2010, is dispensed in child-resistant
single dose foil packaging.
The purpose of this study is to characterize the rates, root
causes, and clinical effects of unintentional exposure to bu-
prenorphine sublingual formulations among young children
and to determine whether these exposures and patient out-
comes differ between formulations.
Methods
This is a retrospective cross-sectional study. Cases of unin-
tentional exposure to any of 3 buprenorphine sublingual for-
mulations involving children aged 28 days to less than 6 years
were obtained from 2 sources. The date range for all events
was October 1, 2009-March 31, 2012. The Researched Abuse,
Diversion, and Addiction-Related Surveillance (RADARS)
System Poison Center Program collects information from
participating poison centers in the US; in the first quarter
of 2012, 49 of 57 US poison centers covering more than
90% of the US population provided data. Methods for the
RADARS System have been described previously.6,13 In brief,
certified specialists in poison information enter clinical infor-
mation as part of patient management. After care is
completed, standardized data fields and de-identified narra-
tive notes are transmitted to the RADARS System, where a
quality control process verifies products involved, exposure
characteristics, and medical outcome. During the second
and third quarters of 2011, this quality control process re-
sulted in revised coding of approximately 37% of buprenor-
phine/naloxone tablet and oral film exposures reported by
regional poison centers to the RADARS System Poison Cen-
ter Program.14 To capture reported exposures from more
than 1 source, the Reckitt Benckiser Pharmaceuticals post-
marketing pharmacovigilance database was also searched
for eligible cases, using 4 search terms from the Medical Dic-
tionary for Regulatory Activities (MedDRA; v 15.0, Northrop
Grumman, Falls Church, Virginia), the standard taxonomy
used by the Food and Drug Administration Adverse Event
Reporting System: “accidental drug intake by child,” “acci-
dental exposure,” “accidental overdose,” and “accidental
poisoning.” Duplicate cases from the Poison Center Program
and pharmacovigilance databases were identified and com-
bined for analysis.
A trained researcher independently reviewed each report to
identify study eligibility, buprenorphine formulation, root
causes for exposure (ie, accessibility/storage, packaging, care-
giver, intended recipient for the medication, and other risk
factors), and adverse events (AEs). Because mandatory
patient and provider education are incorporated in the bu-
prenorphine risk evaluation and mitigation strategies
(REMS) program, data about the relationship between edu-
cation and the exposure were also extracted.15 Data were
passively collected by specialists in poison information for
the purposes of patient care; when no information about a
specific root cause was found in the record, it was impossible
to determine whether the root cause was absent or not asked.1378Therefore, data about identified root causes were presented as
the number of cases in which the root cause was mentioned.
A focused review to collect and classify AEs systematically
was performed on a subset of cases with more serious out-
comes. There was no attempt to differentiate between known
and unexpected side effects, as thismedication is not intended
to be administered therapeutically to young children. Cases
from the Poison Center Programwere reviewed if themedical
outcomewas classified by the specialist in poison information
as moderate effect, major effect, or death, using standard def-
initions established by the American Association of Poison
Control Centers’ National Poison Data System.16 Cases clas-
sified by the specialist in poison information using the medial
outcome codes for “not followed, judged as nontoxic expo-
sure (clinical effects not expected)” and “not followed, mini-
mal clinical effects possible” were excluded. Cases with a
medical outcome of “unable to follow, judged as a potentially
toxic exposure” were included if the level of health care facility
care code or other clinical documentation indicated that the
patient was admitted to the hospital. Cases from themanufac-
turer’s pharmacovigilance database were reviewed by the
panel if they met the age and date criteria and the clinical ef-
fects met the Food and Drug Administration definition of a
serious AE.17 The review panel consisted of 3 experienced
clinicians: a pediatric intensivist/medical toxicologist, a
pediatrician/pharmacoepidemiologist, and an emergency
physician/medical toxicologist. Panel members reviewed
each case to identify all documented AEs. The severity of
each AEwas classified by panel members using CommonTer-
minology Criteria for AEs nomenclature.18 The causal rela-
tionship between each AE and each drug exposure was
determined using standard criteria19,20(Table I; available at
www.jpeds.com). Disagreements were resolved by
consensus. Trained researchers then coded each AE using
MedDRA taxonomy.
Exposures, root causes, and AEs were analyzed using
descriptive statistics. Because the number of children poten-
tially at risk of exposure to buprenorphine could not be esti-
mated, we used buprenorphine prescription fulfillment data
as a surrogate measure of drug availability. Prescription data
were obtained from IMS Health Solutions (Parsippany, New
Jersey), and the number of patients filling prescriptions for
each of the 3 buprenorphine formulations in a geographic
area contributing data to the RADARS System Poison Center
Program during the year-quarter of the exposure (unique re-
cipients of a dispensed drug [URDD]) was used as the de-
nominator for rate calculations.21 A negative binomial
regression model was used to test for difference in average
rates across the 3 drug groups, where URDD was an offset
variable. Average rates were calculated for the year/quarters
during the study period for which each formulation was
available. Unintentional exposure rates, 95% CIs, and tests
of significance were calculated. Two-sided tests were used
for all statistical comparisons. AEs were summarized byMed-
DRA System Organ Class and Preferred Terms.
The operation of the RADARS System Poison Center Pro-
gram is approved by the Colorado Multiple InstitutionalLavonas et al
Table II. Characteristics of children aged 28 days to <6 years with unintentional exposures to buprenorphine
Variable Value
Total buprenorphine*
n = 2380
Buprenorphine
tablets n = 154
Buprenorphine/naloxone
tablets n = 2107
Buprenorphine/naloxone
film n = 118
Sex Male 1229 (51.6%) 74 (48.1%) 1106 (52.5%) 49 (41.5%)
Female 1127 (47.4%) 79 (51.3%) 983 (46.7%) 64 (54.2%)
Not reported 24 (1.0%) 1 (0.6%) 18 (0.9%) 5 (4.2%)
Age group 28-364 d 148 (6.2%) 15 (9.7%) 123 (5.8%) 10 (8.5%)
1 y-<2 y 885 (37.2%) 58 (37.7%) 788 (37.4%) 39 (33.1%)
2 y-<3 y 888 (37.3%) 61 (39.6%) 787 (37.4%) 40 (33.9%)
3 y-<4 y 320 (13.4%) 18 (11.7%) 279 (13.2%) 22 (18.6%)
4 y-<5 y 100 (4.2%) 2 (1.3%) 94 (4.5%) 4 (3.4%)
5 y-<6 y 36 (1.5%) 0 (0.0%) 35 (1.7%) 1 (0.8%)
Exact age not reported 3 (0.1%) 0 (0.0%) 1 (0.0%) 2 (1.7%)
Number of other products
involved in exposure
0 2271 (95.4%) 142 (92.2%) 2016 (95.7%) 112 (94.9%)
1 72 (3.0%) 7 (4.5%) 61 (2.9%) 4 (3.4%)
2 23 (1.0%) 5 (3.2%) 16 (0.8%) 2 (1.7%)
3 or more 14 (0.6%) 0 (0.0%) 14 (0.7%) 0 (0.0%)
Exposure site Own residence 2195 (93.8%) 146 (95.4%) 1942 (93.7%) 107 (93.0%)
Other residence 103 (4.4%) 6 (3.9%) 90 (4.3%) 7 (6.1%)
Unknown 14 (0.6%) 0 (0.0%) 14 (0.7%) 0 (0.0%)
Public area 13 (0.6%) 1 (0.7%) 12 (0.6%) 0 (0.0%)
Health care facility 3 (0.1%) 0 (0.0%) 3 (0.1%) 0 (0.0%)
Other 12 (0.5%) 0 (0.0%) 11 (0.5%) 1 (0.9%)
*Includes data for buprenorphine formulation unspecified (n = 1).
Figure 2. Rates of unintentional exposure to buprenorphine
among children aged 28 days to less than 6 years, adjusted
for drug availability.
November 2013 ORIGINAL ARTICLESReview Board and by the institutional review boards of each
participating center. The authors had full control of all as-
pects of study design, data collection, data analysis and man-
agement, manuscript writing, and the decision to publish.
Reckitt Benckiser Pharmaceuticals was able to review the
manuscript only for proprietary information.
Results
A total of 2380 unique eligible cases were identified (Figure 1;
available at www.jpeds.com). Of these, 154 cases (6.5%)
involved exposure to buprenorphine tablets, 2107 cases
(88.5%) involved exposure to buprenorphine-naloxone
tablets, and 118 cases (5.0%) involved exposure to
buprenorphine-naloxone film (Table II). In 1 additional
case, the record clearly demonstrated a tablet exposure but
did not contain information about whether buprenorphine
or buprenorphine-naloxone tablets were involved. In 109
cases (4.6%), ingestion of at least 1 additional substance was
suspected. The median patient age was 2 years, with no sex
predominance. Although most exposures occurred in the
child’s residence, 145 cases (6.1%) occurred in other locations.
The mean exposure rates were 2.51 cases per 10 000
URDD (95% CI, 2.13-2.95 cases per 10 000 URDD) for bu-
prenorphine tablets, 6.25 (5.92-6.61) cases per 10 000
URDD for buprenorphine-naloxone tablets, and 0.71
(0.59-0.86) cases per 10 000 URDD for buprenorphine-
naloxone film. The mean exposure rates for both tablet for-
mulations were significantly greater than the rate for the
film formulation (rate ratio 8.76 (7.21-10.64) for
combination tablets and 3.51 (2.75-4.50) for single ingre-
dient tablets, P < .001 for both). These relationships were
stable over the 30-month study period (Figure 2).
At least 1 root cause was identified in 1361 (57.2%) of the
2380 cases reviewed. The most commonly identified rootRoot Causes, Clinical Effects, and Outcomes of Unintentional Excauses for unintentional pediatric exposure involved medica-
tion storage, including medication stored in sight (415 cases;
30.5% of cases with a root cause identified and 17.4% of all
cases), medication accessed from a bag or purse (110 cases;
8.1% and 4.6%), and medication stored in a package other
than the original packaging (75 cases; 5.5% and 3.2%)
(Table III). Ingestion of dropped or inappropriately stored
medications was a common identified root cause and
included buprenorphine found in wallets, purses, couches,
automobiles, parents’ pockets, floors, hotel rooms, cups,
cigarette packages, eyeglass cases, cellophane, tissue paper,
breath mint containers, and trash cans. Case notes showed
that buprenorphine was intended for somebody other than
the parent in 374 cases (36.1% and 15.7%), and in 117 casesposures to Buprenorphine by Young Children 1379
Table III. Identified root causes of unintentional exposure to buprenorphine among children aged 28 days to less than 6
years*
Type Detail
Total
buprenorphine†
n = 2380
Buprenorphine
tablets
n = 154
Buprenorphine
naloxone
tablets
n = 2107
Buprenorphine
naloxone film
n = 118
Access/storage Stored in sight, not secure, left out 415(17.4%) 27 (17.5%) 371 (17.6%) 16 (13.6%)
Accessed from bag (purse, diaper bag, luggage, etc) 110 (4.6%) 5 (3.2%) 101 (4.8%) 4 (3.4%)
Drug stored in package other than original packaging
(tissue, plastic wrap, foil, cup, etc)
75 (3.2%) 4 (2.6%) 66 (3.1%) 5 (4.2%)
Patient opened bottle 30 (1.3%) 1 (0.6%) 27 (1.3%) 2 (1.7%)
Mixed medications stored in a bag/bottle 6 (0.3%) 0 (0.0%) 6 (0.3%) 0 (0.0%)
Child resistant cap closure issue 4 (0.2%) 0 (0.0%) 4 (0.2%) 0 (0.0%)
Child resistant cap left open by adult 2 (0.1%) 0 (0.0%) 2 (0.1%) 0 (0.0%)
Behavioral disorders Behavioral disorders 2 (0.1%) 0 (0.0%) 2 (0.1%) 0 (0.0%)
Cutting medication Tablet found in pill cutter or found broken 5 (0.2%) 0 (0.0%) 5 (0.2%) 0 (0.0%)
Developmentally delayed Developmentally delayed (autism, etc) 4 (0.2%) 1 (0.6%) 3 (0.1%) 0 (0.0%)
Diversion Purchased on the street 10 (0.4%) 0 (0.0%) 10 (0.5%) 0 (0.0%)
Obtained from unknown location 4 (0.2%) 1 (0.6%) 3 (0.1%) 0 (0.0%)
Obtained from a friend 3 (0.1%) 0 (0.0%) 3 (0.1%) 0 (0.0%)
Obtained from relative 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%)
Intended recipient Parent’s medication 663 (27.9%) 44 (28.6%) 582 (27.6%) 37 (31.4%)
Others’ medication (uncle, friend of parent,
house guest, boyfriend, etc)
298 (12.5%) 17 (11.0%) 274 (13.0%) 7 (5.9%)
Grandparent’s medication 68 (2.9%) 6 (3.9%) 61 (2.9%) 1 (0.8%)
Sibling’s medication 8 (0.3%) 0 (0.0%) 8 (0.4%) 0 (0.0%)
Mistaken for candy Child thought medication was candy 9 (0.4%) 1 (0.6%) 8 (0.4%) 0 (0.0%)
Other children present Other child present 44 (1.8%) 5 (3.2%) 36 (1.7%) 3 (2.5%)
Sibling administered medication 6 (0.3%) 0 (0.0%) 5 (0.2%) 1 (0.8%)
Other child administered medication 2 (0.1%) 0 (0.0%) 2 (0.1%) 0 (0.0%)
Other risk factors Child protective services/police involved 167 (7.0%) 12 (7.8%) 145 (6.9%) 9 (7.6%)
Evidence or history of child abuse/neglect 18 (0.8%) 0 (0.0%) 17 (0.8%) 0 (0.0%)
Previous accidental unsupervised ingestions in home 13 (0.5%) 2 (1.3%) 11 (0.5%) 0 (0.0%)
Evidence or history of parental drug usage/possession 9 (0.4%) 1 (0.6%) 7 (0.3%) 1 (0.8%)
Parental criminal history/ suspicious behavior 6 (0.3%) 1 (0.6%) 5 (0.2%) 0 (0.0%)
Child left unsupervised 5 (0.2%) 2 (1.3%) 3 (0.1%) 0 (0.0%)
Exposure to medication in utero 5 (0.2%) 1 (0.6%) 4 (0.2%) 0 (0.0%)
Lives with other relative (grandparent, aunt/uncle, etc) 4 (0.2%) 0 (0.0%) 4 (0.2%) 0 (0.0%)
Parent intoxicated 4 (0.2%) 0 (0.0%) 4 (0.2%) 0 (0.0%)
Medication removed from/fell out of intended recipient’s mouth 3 (0.1%) 1 (0.6%) 2 (0.1%) 0 (0.0%)
Other risk factors- other (parental custody issues,
absence of adequate health care)
2 (0.1%) 2 (1.3%) 0 (0.0%) 0 (0.0%)
Unsafe surroundings at home 2 (0.1%) 0 (0.0%) 2 (0.1%) 0 (0.0%)
Child accessed medication after pet exposure 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%)
Evidence or history of family violence 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%)
Ingestion of other hazardous items 1 (0.0%) 1 (0.6%) 0 (0.0%) 0 (0.0%)
Old prescription kept in home 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%)
Special needs child Special needs child 3 (0.1%) 0 (0.0%) 3 (0.1%) 0 (0.0%)
Supervised by alternate
caregiver
Grandparent 62 (2.6%) 4 (2.6%) 55 (2.6%) 3 (2.5%)
Family member (other than grandparent) 23 (1.0%) 0 (0.0%) 23 (1.1%) 0 (0.0%)
Babysitter 21 (0.9%) 1 (0.6%) 17 (0.8%) 3 (2.5%)
Friend of parent 8 (0.3%) 1 (0.6%) 6 (0.3%) 1 (0.8%)
Supervised by mom’s boyfriend/fiance 3 (0.1%) 0 (0.0%) 2 (0.1%) 1 (0.8%)
Visiting another
home/away from
home/outside of
home/homeless
Visiting a friend/neighbor/mother’s boyfriend/house sitting 18 (0.8%) 0 (0.0%) 16 (0.8%) 2 (1.7%)
Visiting a relative 9 (0.4%) 0 (0.0%) 9 (0.4%) 0 (0.0%)
Away from home-other (staying in a hotel, on vacation,
at church camp/retreat)
5 (0.2%) 0 (0.0%) 5 (0.2%) 0 (0.0%)
Exposed while outdoors 3 (0.1%) 0 (0.0%) 3 (0.1%) 0 (0.0%)
Living in homeless shelter/recovery home 3 (0.1%) 0 (0.0%) 2 (0.1%) 1 (0.8%)
*An individual case may have multiple root causes.
†Includes data for buprenorphine formulation unspecified (n = 1).
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caregiver was noted to be supervising the child at the time of
ingestion. Child protective services involvement was
documented in 167 cases (12.3% and 7.0%); case notes rarely1380specified whether this involvement preceded or followed the
exposure. No pattern emerged that differentiated a root
cause by formulation. Clinical notes rarely (2 cases, 0.1%)
contained any data about the effect of patient and providerLavonas et al
Table V. Maximum AE severity in cases undergoing focused review
Maximum AE severity
All formulations*
n = 536
Buprenorphine
tablets n = 38
Buprenorphine/naloxone
tablets n = 471
Buprenorphine/naloxone
film n = 26
Not applicable or panel excluded 17 (3.2%) 0 (0.0%) 16 (3.4%) 1 (3.8%)
Unable to determine 4 (0.7%) 0 (0.0%) 4 (0.8%) 0 (0.0%)
Grade 1, mild 99 (18.5%) 8 (21.1%) 85 (18.0%) 6 (23.1%)
Grade 2, moderate 180 (33.6%) 9 (23.7%) 161 (34.2%) 10 (38.5%)
Grade 3, severe 190 (35.4%) 14 (36.8%) 167 (35.5%) 9 (34.6%)
Grade 4, life-threatening 42 (7.8%) 6 (15.8%) 36 (7.6%) 0 (0.0%)
Grade 5, death 4 (0.7%) 1 (2.6%) 2 (0.4%) 0 (0.0%)
*Includes data for buprenorphine formulation unspecified (n = 1).
November 2013 ORIGINAL ARTICLESeducation required by the buprenorphine REMS, and no
analysis of patient or provider education could be performed.
Focused review by the expert clinical panel was performed
in 536 cases (22.5%), including those of 4 (0.2%) children
who died. Overall, 95.5% of documented AEs were deter-
mined by the panel to be at least potentially related to bupre-
norphine exposure. The most common AEs reported were
lethargy (438 cases), respiratory depression (231), miosis
(197), and vomiting (150), and similar AEs were observed
following exposure to all three formulations (Table IV;
available at www.jpeds.com) Although no cases of life-
threatening toxicity or death were observed in children
who ingested the film, no significant association between
formulation and highest level of AE severity in each case
was found (c2 P = .46; Table V).
Discussion
In this large retrospective study, we found that unintentional
exposure to buprenorphine is frequently associated with se-
vere AEs in young children, and that exposure rates to tablet
formulations, which are typically dispensed in bottles con-
taining a 30-day supply, were 3.5 and 8.8 times the exposure
rates to the film formulation, which is dispensed in single
dose, child-resistant foil packets. Because of its observational
design, this study cannot determine whether the difference in
exposure rates is due to the formulation, packaging, or other
factors. This important poisoning prevention question re-
quires urgent study. Although buprenorphine is a partial
agonist at the mu-opioid receptor, in this group of opioid-
na€ıve children the effects were similar to those of a pure
agonist, and included central nervous system depression, res-
piratory depression, and death.
Our study population is similar to a recent Centers for Dis-
ease Control and Prevention report, which found 59.5%of un-
intentional buprenorphine exposures occurred in boys, 76.8%
involved children aged 1-2 years, and 95.8% involved a bupre-
norphine/naloxone combination product.7 Similar to our re-
sults, a study conducted among US children reported that
ingestion of prescription opioids typically occurred in the
home, at a median age of 2 years, and occurred at higher rates
in regions with greater numbers of opioid prescriptions filled.6
These results are congruent with the observations of Hayes
et al, who reported that lethargy, vomiting,miosis, and respira-
tory depressionwere themost commonpediatricAEs observedRoot Causes, Clinical Effects, and Outcomes of Unintentional Exfollowing unintentional buprenorphine exposures.10 Severe
(grade 3 or higher) clinical effects were reported in 6/86
(7.0%) patients in that series and in approximately 236/2380
(9.9%) patients in our report; the slight difference is likely
due to differences in the study population and analytic
approach.
Our results are also analogous to a recent publication using
data from the Utah Poison Control Center (2002-2011) that
found 94% of 179 exposures to buprenorphine sublingual
formulations among children aged # 5 years involved tablet
rather than the film formulations.22 Similar to our results,
drowsiness (58.6%), vomiting (26.2%), respiratory depres-
sion (19.0%), miosis (15.1%), agitation (10.1%), and tachy-
cardia (8.4%) were the most common reported AEs in
buprenorphine-exposed young children.
We were unable to measure whether the compulsory pa-
tient education, provider education, and medication guide
components of the buprenorphine REMS helped to reduce
pediatric exposures. The education materials, which are
similar across formulations, include specific instructions to
keep buprenorphine products secure and away from chil-
dren.9,15 Nonetheless, improper storage of medication was
a common root cause of buprenorphine exposure.We believe
that an engineered solution, such as providing all potent opi-
oids and other “one pill can kill” medications in single dose,
child resistant packaging, such as a blister pack or foil pouch,
by default, is more likely to be effective than additional efforts
at education. Failure to engage a child-proof cap and/or fail-
ure of the cap to function, though uncommon in our data, is
particularly dangerous because this scenario allows a child to
ingest a large number of pills quickly. Although the Poison
Prevention Packaging Act allows medication to be dispensed
in packaging that is not child resistant, the observation that at
least 15.7% of ingestions involved a medication prescribed
for somebody other than the parent suggests that effective
child resistant packaging is important for many patients
who are secondary caregivers for children.23Whenever young
children are visiting or supervised by grandparents or other
adults who have dangerous medications, additional steps
should be taken to reduce the risk of unintentional exposure.
In contrast to previously published analyses, we were able
to measure and compare pediatric unintentional exposure
event ratios (rates) based on a measure of drug availability
in the community, URDD. Other denominators, such as
the total number of prescriptions, the total amount ofposures to Buprenorphine by Young Children 1381
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patient-days of therapy, or the number of extended dosing
units (ie, tablets or film presentations), can be used to repre-
sent supply.24
Our results are subject to several additional limitations.
Poison center consultations and most manufacturer phar-
macovigilance database reports are passive data collection
systems. As a result, information such as root cause was
not present in the source data for each exposure. Reliance
on spontaneous reporting undercounts the number of
cases, particularly exposures in which clinical effects are
not severe.25 For this reason, the exposure rates we report
do not include all unintentional buprenorphine pediatric
exposures. As in all retrospective studies, a clinical effect
or exposure may have been present but not documented,
and our observations regarding these proportions must
be considered lower bound estimates. Because AEs related
to generic single-ingredient buprenorphine formulations
are unlikely to appear in the Reckitt Benckiser Pharmaceu-
ticals pharmacovigilance database, the estimated rate of ex-
posures to single-ingredient buprenorphine tablets may be
artificially low. Fewer than 2% of cases in this series came
from the pharmacovigilance database, so this effect is likely
minimal.
Most symptomatic children in this series were treated with
naloxone and supportive care, including advanced airway
management in many cases. The spectrum of severity we
observed is less than would have occurred without timely
medical intervention. Because of the comparatively small
number of film formulation exposures, this study was unable
to detect a difference between formulations in severity out-
comes. The panel determined that 0/26 (0%) of film formula-
tion cases and 38/471 (8.1%) of combination tablet cases led
to life-threatening AEs or death. The question about whether
film formulations are associatedwith lesser AE severity should
be revisited when more quarterly data are available.
Although the wide variation in exposure rates to different
buprenorphine formulations is a robust and consistent
observation, unmeasured factors may have led to differential
prescribing. Such differences in the underlying patient popu-
lations may impact the interpretation of risk as it relates to
formulation. In particular, the comparatively low cost of
generic single-ingredient buprenorphine tablets compared
with the combination formulations may have affected pre-
scribing patterns, pediatric exposure rates, and outcomes.
However, as the majority of pediatric exposures were to com-
bination formulations (brand-only during the study period)
and the exposure rate to single-ingredient tablets was inter-
mediate between the exposure rates to the combination tab-
lets and combination film, it is unlikely that cost significantly
influenced our results.
Finally, because standard opioid screening tests do not
detect buprenorphine and definitive testing was rarely per-
formed, the diagnosis of buprenorphine exposure was
made based on exposure history and clinical effects and
may not have been accurate in all cases. Most reports were
missing ingested dose, and those with dose estimates were1382often found to be imprecise or likely to be inaccurate.
Some asymptomatic children may not have ingested bupre-
norphine at all, and in other cases clinical effects attributed
to buprenorphine may have been due to another ingestion
or medical condition. n
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Table I. Standard definitions used to determine AE severity and causal relationship to buprenorphine exposure in cases
undergoing focused review
Causal relationship definitions20 Severity grade definitions19
Related
 History of ingestion consistent with exposure
 Drug levels (if available) consistent with exposure
 Clinical course consistent with exposure
 No other cause of event evident
Grade 1: mild
 Symptoms: asymptomatic or mild
 Therapy: clinical observation or diagnostic studies only; intervention not indicated
At least potentially related
 History of ingestion consistent with exposure
 Drug levels (if available) consistent with exposure
 Clinical course consistent with exposure
 Other cause of event unlikely
 Drug may have been secondary cause of event
Grade 2: moderate
 Symptoms: minimal; limiting more complex and newly-acquired age-appropriate
instrumental activities of daily living
 Therapy: local or noninvasive intervention indicated for this event
Unlikely related
 No clear history of ingestion
 Drug levels (if available) inconsistent with exposure
 Clinical course inconsistent with exposure
 Other cause of event possible
Grade 3: severe
 Symptoms: severe or medically significant but not immediately life-threatening; disabling;
limiting simple, basic, and long-mastered activities of daily living
 Therapy: hospitalization or prolongation of hospitalization
Unable to determine
 Not enough case detail to evaluate the
relationship of drug exposure to the event
Grade 4: life-threatening
 Symptoms: life-threatening
 Therapy: urgent intervention indicated
Grade 5: death
 Death related to exposure
Unable to determine
 Not enough case detail to evaluate the severity of the event
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Figure 1. Case processing summary.
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Table IV. AEs related or potentially related to buprenorphine exposure in 536 cases under going focused review
Buprenorphine tablets Buprenorphine/naloxone tablets Buprenorphine/naloxone film
System organ class Preferred term
Cardiac disorders Tachycardia (9), bradycardia (2), arrhythmia (1),
cardiac arrest (1), cyanosis (1), myocardial infarction (1),
Tachycardia (51), bradycardia (42), cyanosis (15), cardiac arrest (2) Bradycardia (3)
Eye disorders miosis (10), eyelid ptosis (1), pupil fixed (1) Miosis (172), eye movement disorder (2), gaze palsy (2), eye edema (1), mydriasis (1) Miosis (13)
Gastrointestinal disorders Vomiting (7) Vomiting (134), nausea (4), gastrointestinal sounds abnormal (3), constipation (2),
abdominal pain (1), abdominal pain upper (1), diarrhea (1), dry mouth (1),
oral pruritus (1), salivary hypersecretion (1)
Vomiting (4)
General disorders and
administration
site conditions
Irritability (5), pyrexia (2), death (1), hypothermia (1) Irritability (33), pyrexia (11), death (1), fatigue (1), feeling cold (1), sluggishness (1) Gait disturbance (1)
Nervous system disorders Lethargy (36), ataxia (5), brain edema (1), dizziness (1),
nystagmus (1), unresponsive to stimuli (1)
Lethargy (375), ataxia (38), somnolence (28), depressed level of consciousness (6),
dizziness (6), dysarthria (5), coma (4), loss of consciousness (3), tremor (3),
convulsion (2), syncope (2), tardive dyskinesia (2), tongue paralysis (2),
balance disorder (1), brain edema (1), drooling (1), dyskinesia (1), psychomotor
hyperactivity (1)
Lethargy (23), ataxia (3), dysarthria (1),
psychomotor hyperactivity (1)
Psychiatric disorders Agitation (6) Agitation (62), confusional state (8), abnormal behavior (3), hallucination (3),
restlessness (2), aggression (1), breath holding (1), staring (1)
Agitation (2), confusional state (1)
Respiratory, thoracic, and
mediastinal disorders
Respiratory depression (17), bronchospasm (1), increased
bronchial secretion (1), pneumonia aspiration (1),
respiratory arrest (1), stridor (1)
Respiratory depression (200), wheezing (6), respiratory arrest (4), stridor (4),
dyspnea (3), hypoxia (3), apnea (2), atelectasis (2), cough (2), hypopnea (2),
pneumonitis (2), respiratory failure (2), bronchospasm (1), hypoventilation (1),
pulmonary edema (1), rhonchi (1), sneezing (1), tachypnea (1)
Respiratory depression (14),
bronchospasm (1)
Vascular disorders Hypotension (6), pallor (2), hemorrhage (1), hypertension (1) Hypotension (37), hypertension (9), flushing (6), pallor (6) Hypotension (3), flushing (2), pallor (1)
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